Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma Allarity Therapeutics A/SMarch 9, 2021 GMT - Treatment of animal osteosarcoma models with dovitinib increased the median survival time by 50 % as compared to control animals. Press release Hørsholm, Denmark (9 March 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced positive data from its preclinical assessment of dovitinib’s antitumor activity in osteosar...